NMN (Nicotinamide Mononucleotide): Chemistry, Transport and NAD+ Precursor Research

NMN occupies the penultimate position of the NAD+ salvage route. Nicotinamide phosphoribosyltransferase condenses nicotinamide with phosphoribosyl pyrophosphate to yield NMN, and NMN adenylyltransferases 1 to 3 then join it to the adenylyl group of ATP, producing NAD+. Molecular formula C11H15N2O8P; monoisotopic mass 334.0566 daltons.

Structurally the molecule is exactly half of NAD+ with the pyrophosphate bridge cut. Nicotinamide is attached to carbon 1 of a ribofuranose ring through a beta-N-glycosidic bond at the ring nitrogen, which makes that nitrogen quaternary and gives the pyridinium ring a permanent positive charge; a phosphate monoester occupies the 5-prime hydroxyl. Balance of those two charges is why PubChem records a formal charge of zero for CID 14180 despite the quaternary centre. The polarity descriptors follow from the same architecture: XLogP minus 3.5, topological polar surface area 166 square angstroms, four hydrogen-bond donors and eight acceptors.

Endogenous abundance is low and dietary abundance is lower still. Mills and colleagues reported concentrations of 0.25 to 1.88 mg per 100 g in edamame, broccoli, cucumber and cabbage, and 0.26 to 1.60 mg per 100 g in avocado and tomato, in Cell Metabolism in 2016. Those figures are two to three orders of magnitude below the quantities used in the human trials described below, which is the arithmetic reason food sources and supplementation research are not comparable subjects.

NMN cannot cross a lipid bilayer unaided, so every account of cellular entry requires either a carrier or a chemical modification at the cell surface. Grozio and colleagues proposed the carrier answer in Nature Metabolism in 2019, identifying the gene Slc12a8 as a sodium-dependent NMN transporter enriched in murine small intestine and itself regulated by NAD+.

Kinetics in that paper put the Michaelis constant at 34.1 plus or minus 8.3 micromolar in overexpressing NIH3T3 cells. Selectivity was narrow: the carrier moved NMN but not nicotinamide riboside, and in reconstituted proteoliposomes replacing sodium with lithium cut tritiated NMN incorporation by roughly 80 percent, while chloride proved dispensable. Knockdown lowered NAD+ in jejunum and ileum, and expression rose in the aged ileum.

Contestation followed within months. Schmidt and Brenner published a matters-arising piece in the same journal in 2019 titled as an absence of evidence for the assignment, disputing the analytical methods and the transport data; the original authors replied in the same issue. Neither side conceded, and the honest summary is that the assignment is reported and disputed rather than settled. A parallel and less contested route runs outside the cell: the ecto-5-prime-nucleotidase CD73 removes the phosphate to give nicotinamide riboside, which equilibrative nucleoside transporters carry inward, after which nicotinamide riboside kinases 1 and 2 restore the phosphate. Under that model extracellular NMN is a reservoir rather than a passenger. Cissé and colleagues returned to the carrier question in iScience in 2026 with brain electrophysiology, reporting that mice lacking Slc12a8 failed to respond to NMN in the supramammillary nucleus, which is a functional rather than a biochemical argument for the gene mattering.

NMN taken by mouth meets the gut microbiota before it meets a transporter, and isotope tracing published in 2025 reframed that encounter. Yaku and colleagues reported in Science Advances that only a small portion of oral NMN was absorbed intact from mouse small intestine, most being converted by gut bacteria to nicotinic acid.

A second arm of the same work bypassed the gut entirely and produced a comparable result. Compounds delivered straight into the bloodstream were rapidly degraded to nicotinamide and secreted into bile, where microbial deamidation again generated nicotinic acid that returned to the liver for NAD+ synthesis through the Preiss-Handler route. Enterohepatic circulation, on that account, does much of the work attributed to the intact precursor, and the liver preferentially uses the recycled deamidated form.

Circulating measurements are consistent with limited but real appearance of the intact molecule. Pencina and colleagues reported in the Journal of Gerontology in 2023 that a microcrystalline polymorph given at 1,000 mg once or twice daily for 14 days to 32 adults aged 55 to 80 raised blood NMN 1.7-fold and 3.7-fold above baseline respectively, with NAD+ metabolome members higher at days 8 and 14. Blood NMN and tissue NMN remain separate quantities, and no human study has resolved the second one.

NMN trials in humans have measured one analyte well and clinical endpoints poorly. Yi and colleagues randomized 80 middle-aged healthy adults in a multicentre trial reported in GeroScience in 2023, comparing placebo against 300, 600 and 900 mg daily for 60 days, and found blood NAD significantly raised in every active group at day 30 and day 60.

Two 12-week trials at 250 mg per day, the quantity matching a single 250 mg tablet, tell a similar story. Katayoshi and colleagues gave 36 healthy middle-aged participants 125 mg twice daily in Scientific Reports in 2023 and found serum nicotinamide significantly higher than placebo, while pulse wave velocity trended downward without reaching a significant between-group difference. Morifuji and colleagues studied 60 older adults in GeroScience in 2024 and reported significantly higher blood NAD+ and metabolite levels, while the pre-specified primary stepping-test outcome showed no significant difference at either 4 or 12 weeks.

Pooled analysis has sharpened the same asymmetry. A 2026 systematic review in Nutrients assembled 15 trials spanning 250 to 2,000 mg daily and 14 days to 24 weeks, and found no significant pooled effect on fasting glucose, glycated haemoglobin or lipid measures. A 2026 post hoc analysis of the 80-participant trial, published in GeroScience, is more useful as chemistry than as clinical inference: baseline whole-blood NAD sat at a median 7.21 nanomolar with an interquartile range of 5.5 to 10.6, and increases in NAD tracked small increments in haemoglobin, at 0.027 percent per unit with a 95 percent confidence interval of 0.010 to 0.045, and in red blood cell count. Raising the analyte is reproducible; converting that into an endpoint is not.

NMN appears across an unusually wide range of 2026 rodent model systems, and the mechanistic reports are more specific than the clinical ones. Cissé and colleagues recorded from mouse supramammillary nucleus in iScience in 2026, finding that NMN raised burst firing in neurons expressing Slc12a8 and restored aged-animal rates toward young values.

Hepatic work published in the British Journal of Pharmacology in 2026 used aflatoxin B1 at 0.75 mg per kg as the insult and beta-NMN at 300 mg per kg as the intervention, and traced the protective signal to the gut microbiota, bile acid and farnesoid X receptor axis; deleting intestinal FXR signalling abolished the effect, which localises the mechanism outside the liver despite the liver being where injury was scored. A separate 2026 report in the Journal of Cardiovascular Translational Research described NMN raising SIRT3 in diabetic mouse myocardium, with reduced acetylation of GSK3-beta and reduced Smad3 phosphorylation accompanying lower alpha-smooth-muscle-actin and collagen I.

Formulation chemistry is the other active thread, and it exists because of the polarity problem described earlier. Lin and colleagues characterised lactoferrin-modified lipid nanoparticles in Frontiers in Chemistry in 2026 at approximately 147 nanometres mean particle size, 5.02 percent loading capacity and 41.8 percent surface modification, reporting 62 percent permeability in their blood-brain barrier model. A chitosan-based pH-responsive system published in Colloids and Surfaces B in 2026 reached 86.53 percent encapsulation efficiency with roughly 70 percent cumulative release at pH 7.4. Encapsulation is the same admission in two different chemistries: the free molecule does not distribute well on its own.

NMN is manufactured by chemical phosphorylation of nicotinamide riboside, by chemoenzymatic routes, and increasingly by whole-cell or multi-enzyme biocatalysis, and the last of these is where the recent optimisation literature sits. Cost in enzymatic routes is dominated by ATP consumption, since nicotinamide phosphoribosyltransferase and the upstream phosphoribosyl pyrophosphate supply both draw on it.

Tang and colleagues addressed exactly that in the Journal of Agricultural and Food Chemistry in 2025, engineering ATP recycling into a cascade and optimising reaction conditions. Reported enzyme activity reached 21.9 plus or minus 0.65 units per millilitre, ATP regeneration improved 2.3-fold over the conventional arrangement, and the final titre reached 14.6 plus or minus 0.51 grams per litre, roughly 5.4 times the starting yield. A 2025 review in Synthetic and Systems Biotechnology mapped the wider pathway network and identified the rate-limiting enzymes that such work targets, and separate 2025 work examined the bacterial PnuC nucleoside transporter as a way to move intermediates across the production strain membrane.

Characterisation rests on chromatography rather than mass alone, for a specific structural reason. Reversed-phase methods resolve the molecule with ultraviolet detection at 266 nm, and Xiang and colleagues published a validated procedure in 2023 on a C18 column of 4.6 by 250 millimetres at 5 micrometres, 30 degrees Celsius, 1.0 millilitre per minute, with a methanol and ammonium formate gradient. Mass spectrometry alone cannot distinguish the beta anomer from the alpha anomer, since the two share formula and exact mass, so anomeric assignment requires chromatographic separation or nuclear magnetic resonance. The two expected related substances follow from the two cleavable bonds: nicotinamide from hydrolysis of the glycosidic bond, and nicotinamide riboside from loss of the phosphate.

NMN is supplied as a white to off-white crystalline or lyophilized solid, and in the linked catalogue item as 250 mg per tablet. Being a phosphate ester of a glycosylated pyridinium salt, the material is freely water-soluble and strongly hygroscopic, so ambient humidity is the first variable a storage record should name.

Solution stability has been measured directly. Xiang and colleagues characterised degradation in 2023 using a validated reversed-phase method and reported apparent first-order kinetics in aqueous solution at room temperature, with published t0.9 and t1/2 values of 95.58 and 860.26 hours. Degradation accelerated with temperature and with departure from neutrality in either direction, strong acid and strong base both being destructive, while exposure to pepsin and trypsin produced minimal loss. The practical reading is that pH and temperature, rather than proteolytic exposure, are the variables worth controlling.

Two structural liabilities define what a purity record should resolve. The beta-N-glycosidic bond hydrolyses to release nicotinamide, and the 5-prime phosphate monoester can be cleaved to give nicotinamide riboside, so a chromatogram reporting a single main-peak percentage without naming those two related substances is uninformative. Detection at 266 nm on a C18 column with a methanol and ammonium formate gradient is the published arrangement. Because the alpha and beta anomers are indistinguishable by formula and exact mass, anomeric identity must be established chromatographically or by nuclear magnetic resonance rather than by mass spectrometry alone. Solid-state form also matters: the polymorph studied in the 2023 pharmacokinetic work was specified as a microcrystalline material rather than an amorphous one, which is the kind of detail that belongs in a certificate of analysis. Research use only, in vitro laboratory work; not for human or veterinary use.